Legal & General Group
MAZE

Legal & General Group’s Maze Therapeutics MAZE Stock Holding History

Legal & General Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Buy
5,790
+411
+8% +$18.1K ﹤0.01% 2557
2025
Q4 		$223K Buy
5,379
+160
+3% +$5.5K ﹤0.01% 2570
2025
Q3 		$135K Buy
5,219
+977
+23% +$16.5K ﹤0.01% 2616
2025
Q2 		$52K Buy
4,242
+3,371
+387% +$35.1K ﹤0.01% 2705
2025
Q1 		$9.59K Buy
+871
New +$10.5K ﹤0.01% 3178

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's MAZE Position: Q1 2026 in Review

Legal & General Group increased its Maze Therapeutics (MAZE) stake by 7.6% in Q1 2026, buying an estimated $18.1K and bringing the position to 5,790 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Legal & General Group first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $223K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Legal & General Group held 5,790 shares of Maze Therapeutics worth $173K as of Q1 2026.
  • Legal & General Group bought 411 Maze Therapeutics shares in Q1 2026, an estimated $18.1K.
  • Maze Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2557 holding.
  • Legal & General Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Legal & General Group's Maze Therapeutics position peaked at $223K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.